Lytix Biopharma AS (6BG) Stock Statistics & Valuation Metrics
Total Valuation
Lytix Biopharma AS has a market cap or net worth of EUR 59.06M. The enterprise value is EUR 617.86M.
- Market Cap
- EUR 59.06M
- Enterprise Value
- EUR 617.86M
Share Statistics
Lytix Biopharma AS has 76,900,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 76,900,000
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Lytix Biopharma AS’s return on equity (ROE) is -0.87 and return on invested capital (ROIC) is -86.76%.
- Return on Equity (ROE)
- -0.87
- Return on Assets (ROA)
- -0.64
- Return on Invested Capital (ROIC)
- -86.76%
- Return on Capital Employed (ROCE)
- -0.87
- Revenue Per Employee
- 795.21K
- Profits Per Employee
- -6.73M
- Employee Count
- 14
- Asset Turnover
- 0.08
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Lytix Biopharma AS is -6.60. Lytix Biopharma AS’s PEG ratio is -0.49.
- PE Ratio
- -6.60
- PS Ratio
- 965.55
- PB Ratio
- 6.17
- Price to FCF
- -9.96
- Price to Operating Cash Flow
- -9.96
- PEG Ratio
- -0.49
Income Statement
In the last 12 months, Lytix Biopharma AS had revenue of 11.13M and earned -94.27M in profits. Earnings per share was -1.74.
- Revenue
- 11.13M
- Gross Profit
- -23.46M
- Operating Income
- -95.90M
- Pretax Income
- -94.27M
- Net Income
- -94.27M
- EBITDA
- -93.22M
- Earnings Per Share (EPS)
- -1.74
Cash Flow
In the last 12 months, operating cash flow was -58.93M and capital expenditures 0, giving a free cash flow of -58.93M billion.
- Operating Cash Flow
- -58.93M
- Free Cash Flow
- -58.93M
- Free Cash Flow per Share
- -0.86
Dividends & Yields
Lytix Biopharma AS pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -10.04%
- Earnings Yield
- -15.16%
Stock Price Statistics
- Beta
- 0.23
- 52-Week Price Change
- 11.53%
- 50-Day Moving Average
- 0.73
- 200-Day Moving Average
- 0.82
- Relative Strength Index (RSI)
- 45.69
- Average Volume (3m)
- 130
Important Dates
Lytix Biopharma AS upcoming earnings date is Nov 11, 2026, Before Open (Not Confirmed).
- Last Earnings Date
- Aug 27, 2026
- Next Earnings Date
- Nov 11, 2026
- Ex-Dividend Date
- ―
Financial Position
Lytix Biopharma AS as a current ratio of 3.91, with Debt / Equity ratio of 2.45%
- Current Ratio
- 3.91
- Quick Ratio
- 3.91
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.37
- Interest Coverage Ratio
- -761.08
Taxes
In the past 12 months, Lytix Biopharma AS has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Lytix Biopharma AS EV to EBITDA ratio is -5.31, with an EV/FCF ratio of -8.01.
- EV to Sales
- 776.37
- EV to EBITDA
- -5.31
- EV to Free Cash Flow
- -8.01
- EV to Operating Cash Flow
- -8.01
Balance Sheet
Lytix Biopharma AS has EUR 117.90M in cash and marketable securities with EUR 2.88M in debt, giving a net cash position of EUR 115.02M billion.
- Cash & Marketable Securities
- EUR 117.90M
- Total Debt
- EUR 2.88M
- Net Cash
- EUR 115.02M
- Net Cash Per Share
- EUR 1.50
- Tangible Book Value Per Share
- EUR 1.39
Margins
Gross margin is 100.00%, with operating margin of -14909.54%, and net profit margin of -14639.14%.
- Gross Margin
- 100.00%
- Operating Margin
- -14909.54%
- Pretax Margin
- -14639.14%
- Net Profit Margin
- -14639.14%
- EBITDA Margin
- -14611.84%
- EBIT Margin
- -14764.97%
